Respiri Limited
RSH.AX
Australian Securities Exchange0.03
AUD
- -
- -
Respiri Limited
RSH.AX
(Australian Securities Exchange)
Recent
price
0.03
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Vitasora Health Limited Vitasora Health Limited, formerly Respiri Limited Respiri Limited, operates as an Australian e-Health software-as-a-service company focused on remote patient monitoring and chronic disease management, primarily targeting the US healthcare market; it develops and commercializes medical devices and mobile health applications including wheezo, a world-first FDA-approved Class II electronic wheeze detection tool that analyzes breath sounds for airway limitation in asthma, COPD, and other respiratory conditions; the respiri mobile app for symptom logging, triggers, medication tracking, and weather integration; and the Respiri health portal for data sharing with physicians and caregivers. The company provides customizable reimbursement programs qualifying for US Current Procedural Terminology codes in remote patient monitoring, chronic care management, and telehealth services for chronic conditions encompassing respiratory disorders with wheeze detection, cardiovascular disease, diabetes, and obesity; these programs integrate seamlessly with healthcare providers' workflows to enhance patient outcomes, reduce costs, and generate revenue through CMS-approved billing. Vitasora Health Limited maintains operations across Australia, the US, and the Philippines, serving healthcare organizations, physicians, and health systems with a disruptive model that extends care beyond clinics via data-driven insights and clinical expertise. Founded in 1987 and headquartered at 432 St Kilda Road, Melbourne, Victoria, the company listed on the ASX in 2000 under ticker RSH before transitioning to VHL in April 2025 following shareholder approval to reflect its evolution into a full-service connected care management provider. Recent developments include the January 2025 completion of its US$9 million acquisition of Orb Health Inc., a Texas-based connected care firm providing remote patient monitoring and chronic care management, which adds 5,500 enrolled patients, drives A$3.5 million in annual cost synergies, over A$2 million in first-year cross-selling revenue, and accelerates US profitability; a September 2024 partnership contract between Respiri and Ceras with Covenant Health for expanded service delivery; and a March 2025 A$4 million capital raise via placement to support growth and the name change.